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Although HLA class I alleles can bind epitopes up to
14 amino acids in length, little is known about the immu-
nogenicity or the responding T-cell repertoire against
such determinants. Here, we describe an HLA-B*3508-
restricted cytotoxic T lymphocyte response to a 13-mer
viral epitope (LPEPLPQGQLTAY). The rigid, centrally
bulged epitope generated a biased T-cell response. Only
the N-terminal face of the peptide bulge was critical for
recognition by the dominant clonotype SB27. The SB27
public T-cell receptor (TcR) associated slowly onto the
complex between the bulged peptide and the major histo-
compatibility complex, suggesting significant remodeling
upon engagement. The broad antigen-binding cleft of
HLA-B*3508 represents a critical feature for engagement
of the public TcR, as the narrower binding cleft of HLA-
B*3501LPEPLPQGQLTAY, which differs from HLA-B*3508 by
a single amino acid polymorphism (Arg156 3 Leu), inter-
acted poorly with the dominant TcR. Biased TcR usage in
this cytotoxic T lymphocyte response appears to reflect a
dominant role of the prominent peptidemajor histocom-
patibility complex class I surface.
Cytotoxic T lymphocytes (CTLs)1 recognize short peptide
fragments (1, 2), usually 8–10 amino acids in length, com-
plexed to major histocompatibility complex class I (MHC-I)
molecules (pMHC-I) (3, 4). Foreign peptides presented to CTLs
make specific side chain interactions with anchor sites in the
MHC-I binding groove (5). MHC-I can ligate a diverse array of
antigenic peptides because of the high degree of polymorphism
within the six pockets of the antigen-binding cleft (6). Selection
of peptides that bind the MHC-I cleft is usually determined by
only two pockets that specify primary anchor sites (7) with one
or more secondary anchor sites that fine-tune the binding mo-
tifs for individual MHC-I allotypes (8). For example, the com-
mon MHC-I molecule HLA-B35 preferentially binds peptide
ligands with proline as a dominant anchor residue at position 2
(P2) and generally a tyrosine at the C terminus (P) (9–11). In
addition, secondary anchor positions can also influence allele-
specific binding (3, 9, 12, 13). MHC-I polymorphism not only
diversifies selection of antigens (8), but also broadens the T-cell
repertoire that is used to recognize pathogens (14–17). Even
single amino acid differences in MHC molecules can exert
significant effects on T-cell repertoire selection, patterns of
alloreactivity, peptide ligand selection, antigen processing, and
susceptibility to viral pathogens (17–19).
In general, the size limitation of peptides that bind to MHC-I
is dictated by a hydrogen bonding network, highly conserved
between different class I molecules, at the N- and C-terminal
ends of the antigen-binding cleft (20–22). Nevertheless, despite
these restrictions, some longer peptides can bind to MHC-I
(23–29). These longer epitopes can either extend beyond the
conventional C-terminal anchor site (29, 30) or bulge centrally
from the antigen-binding cleft (25, 28, 31). An extreme example
of accommodating a lengthy class I-restricted peptide was ob-
served in rat MHC-I RT1-Aa complexed to a 13-mer epitope,
MTF-E (25). The crystal structure of this binary complex re-
veals a highly solvent-exposed, centrally bulged peptide that
displays sufficient mobility to adopt two different conforma-
tions within the antigen-binding cleft. Solvent-exposed saccha-
ride residues in glycopeptides presented by MHC molecules
have also been observed to protrude substantially from the
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peptide-binding groove (32). Recently, unusually long MHC-II-
restricted epitopes have been shown to adopt a -hairpin struc-
ture at the C-terminal end of the peptide-binding groove (33);
however, this has not been observed for longer class I peptides.
Despite the description of unusually long self-peptides being
naturally presented, the role of longer epitopes in antiviral
immunity is poorly understood. The prevalence of such epitopes
in immunity and the factors governing the processing and
presentation of these epitopes are largely unknown. Moreover,
how a T-cell receptor (TcR) engages such a pMHC complex and
the nature of the T-cell repertoire elicited from such a unique
pMHC complex are unknown. However, it has been suggested
that prominently bulged peptides may prevent many TcRs
from approaching the surface of the MHC molecule, thereby
limiting the potential immunogenicity of unusually long class
I-binding antigenic peptides (28). Consistent with this view,
immunodominant viral epitopes 11 amino acids in length
have not been well described in antiviral CD8 T-cell
responses.
To begin to address such issues, we have investigated the
immune response to Epstein-Barr virus (EBV), a ubiquitous
human pathogen. The CTL response to the very immunogenic
lytic antigen BZLF1 includes a cluster of three overlapping
sequences of different lengths, a 9-mer (56LPQGQLTAY64), an
11-mer (54EPLPQGQLTAY64), and a 13-mer (52LPEP-
LPQGQLTAY64), that may form HLA-B*3501-restricted
epitopes (27). All peptides bind well to HLA-B*3501; however,
the CTL response in individuals expressing this allotype is
directed exclusively toward the 11-mer (27). However, the 13-
mer epitope (LPEPLPQGQLTAY) is the exclusive target for the
CTL response in individuals expressing the HLA-B*3508 al-
lele, which differs from HLA-B*3501 by a single Leu156 3 Arg
substitution (27). The above observations are examples of pep-
tide immunodominance (27). In this study, we provide a struc-
tural basis for the presentation of long HLA-B35-restricted
epitopes and show the restricted nature of the T-cell response
(T-cell immunodominance) to these unusual ligands.
EXPERIMENTAL PROCEDURES
Cell Lines—Lymphoblastoid cell lines were established by exogenous
transformation of peripheral B-cells with EBV derived from the super-
natant of the B95.8 cell line and were maintained in growth medium
(10% fetal calf serum and RPMI 1640 medium). The mutant lympho-
blastoid cell line  T lymphoblastoid hybrid cell line 174xCEM.T2
(referred to as T2 cells) (34), expressing HLA-B*3508 (T2.B*3508) (27,
35), was also used in this study. Phytohemagglutinin (PHA) blasts were
generated by stimulating peripheral blood mononuclear cells (PBMCs)
with PHA (Sigma), and after 3 days, growth medium containing super-
natant from the interleukin-2-producing cell line MLA-144 (European
Collection of Cell Cultures) and recombinant interleukin-2 (rIL-2) were
added. PHA blasts were propagated with biweekly replacement of rIL-2
and MLA-144 supernatant (PHA-free) for up to 8 weeks. The blood
donors used in this study were healthy laboratory staff selected for
particular HLA alleles, and prior exposure to EBV was assessed by
standard virus-specific antibody tests. All cell lines were regularly
screened for mycoplasma contamination.
CTL Cultures—CTL clones were generated by agar cloning as fol-
lows. PBMCs (2  106) were stimulated in 2 ml of growth medium with
autologous PBMCs that had been precoated with the LPEP-
LPQGQLTAY peptide at 1 M for 1 h (responder/stimulator ratio of 2:1).
After 3 days, cells were dispersed and seeded on 0.35% (w/v) agarose
(Seaplaque, BioWhittaker Molecular Applications, Rockland, ME) con-
taining RPMI 1640 medium, 20% (v/v) fetal calf serum, and 25% (v/v)
supernatant from MLA-144 cultures and rIL-2 (50 units/ml). Colonies
were harvested after an additional 3–5 days and amplified in culture
with biweekly restimulation with rIL-2, MLA-144 supernatant, and
-irradiated (8000 rads) autologous lymphoblastoid cell lines that had
been prelabeled with the LPEPLPQGQLTAY peptide at 0.1 M for 1 h
and washed three times.
Cytotoxicity Assay/Fine Specificity Analysis—CTL cultures were
tested in duplicate or triplicate for cytotoxicity in a standard 5-h chro-
mium release assay. Briefly, CTLs were assayed against 51Cr-labeled
PHA blast targets that were pretreated with synthetic peptide or left
untreated. Percent specific lysis was calculated, and the peptide con-
centration required for half-maximum lysis was determined from dose-
response curves. To reduce spontaneous lysis of PHA blast target cells,
the medium used in the chromium release assays was supplemented
with rIL-2. Peptides were synthesized by Mimotopes Ltd. (Clayton,
Victoria, Australia). Toxicity testing of all peptides was performed prior
to use by adding peptide to 51Cr-labeled PHA blasts in the absence of
CTL effectors. A -scintillation counter (Topcount Microplate, Packard
Instrument Co.) was used to measure 51Cr levels in assay supernatant
samples. The mean spontaneous lysis for target cells in the culture
medium was always 20%, and the variation about the mean specific
lysis was 10%.
Flow Cytometric Analysis—PBMCs or bulk T-cell cultures were in-
cubated for 30 min at 4 °C with a phycoerythrin-labeled HLA-
B*3508LPEPLPQGQLTAY tetramer (Proimmune Ltd., Oxford, UK). Cells
were then washed and labeled for 30 min at 4 °C with TRI-COLOR®-
labeled anti-human CD8 antibody (Caltag Laboratories, Burlingame,
CA), allophycocyanin-labeled anti-human CD3 antibody (Pharmingen),
and one of the following fluorescein isothiocyanate-labeled TcR chain-
specific antibodies (Serotec, Oxford): V1 (TRBV9), V2 (TRBV20-1),
V3 (TRBV28), V5.1 (TRBV5-1), V5.2 (TRBV5-6), V5.3 (TRBV5-5),
V6.7 (TRBV7-1), V7 (TRBV4), V8 (TRBV12), V11 (TRBV25-1),
V12 (TRBV10), V13.1 (TRBV6-5), V13.6 (TRBV6-6), V14
(TRBV27), V16 (TRBV14), V17 (TRBV19), V18 (TRBV18), V20
(TRBV30), V21.3 (TRBV11-1), V22 (TRBV2), or V23 (TRBV13).
Cells were washed and analyzed by flow cytometry on a FACSCalibur
using CellQuest software (BD Biosciences). Cell sorting was performed
on a MoFlo high proficiency cell sorter (Cytomation, Inc., Fort Collins,
CO).
T-cell Repertoire Analysis—T-cell clones were verified for purity and
peptide specificity by flow cytometry with an HLA-B*3508LPEPLPQGQLTAY
tetramer before TcR analysis was performed. Total RNA was extracted
from T-cell clones and tetramer sorted bulk CTL cultures using TRIzol
reagent. Reverse transcription was performed with Superscript III (In-
vitrogen) and antisense TcR and TcR chain primers. PCR was per-
formed in a 25-l volume consisting of 200 M dNTPs, 20 mM MgCl2, and
1.25 units of AmpliTaq Gold (Applied Biosystems, Foster City, CA) using
a TcR constant primer and 1 of 24 TcR V family-specific primers or a
TcR C constant primer and 1 of 34 TcR V family-specific primers (36).
PCR products were purified and ligated into the pGEM-T vector system
(Promega Corp., Madison, WI) and sequenced using the ABI PRISM
BigDye terminator reaction kit (Applied Biosystems). Nomenclature for
TcR usage is based on the International ImMunoGeneTics Information
System (37).
Expression, Purification, and Crystallization of HLA-B35 Alleles in
Complex with Long Epitopes—Soluble HLA-B*3501 and HLA-B*3508
molecules (residues 1–276) and full-length 2-microglobulin (residues
1–99) were expressed, refolded with the LPEPLPQGQLTAY peptide,
purified, and concentrated to 10 mg/ml as described previously (38). The
HLA-B35 crystals were obtained by the hanging drop vapor diffusion
technique. Large (0.7  0.5  0.3 mm) block-shaped crystals grew
within 5 days in 0.2 M ammonium acetate and 17% (w/v) polyethylene
glycol 3350 (100 mM cacodylate (pH 7.6)) at 4 °C.
X-ray Data Collection and Structure Determination—Crystals were
directly transferred to cryoprotectant-containing 20% glycerol and
flash-frozen prior to data collection. Data were collected on an in-house
radiation source and at the Advanced Photon Source (Argonne National
Laboratory, Argonne, IL). Data were processed and scaled using the
HKL suite (see Table I) (39).
The HLA-B35 complex structures were refined from an HLA-B*3501
structure that was previously determined in our laboratory.2 The model
was manually built using program O (40) and improved through mul-
tiple rounds of refinement using the CNS suite (41). The progress of
refinement was monitored by Rfac and Rfree values. Rigid body refine-
ment and simulated annealing were used in the first instance, but in
later rounds, energy minimization and B-individual refinement were
used to improve the quality of the model. See Table I for the final
refinement and model statistics.
TcR Cloning, Expression, and Refolding—The genes encoding
TRAV19 and TRBV6-1 were cloned from the HLA-B*3508-restricted,
13-mer-specific T-cell clone SB27. DNA encoding the extracellular do-
mains of TRAV19 and TRBV6-1 and terminating immediately before
the interchain extracellular cysteines was cloned into the pET30 ex-
2 N. A. Borg, J. Rossjohn, S. R. Burrows, and J. McCluskey, unpub-
lished data.
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pression vector (Novagen). DNA encoding the unpaired cysteine at
position 77 of TRBV6-1 was mutated to encode an alanine. Additionally,
DNA was mutated to encode a cysteine in the constant domain of both
TRAV19 (Thr48 3 Cys) and TRBV6-1 (Ser57 3 Cys) (75). TRAV19 and
TRBV6-1 were expressed, refolded, and purified as described previously
(76), except that the protein was refolded in the presence of 5 M urea.
Biacore Measurements and Analysis—All surface plasmon resonance
experiments were carried out at 25 °C on a Biacore 3000 instrument
using 10 mM HEPES-HCl (pH 7.4), 150 mM NaCl, and 0.005% (v/v)
surfactant P20 (supplied by the manufacturer) supplemented with 1%
(w/v) bovine serum albumin to inhibit nonspecific binding. Antibody
12H8 (42) was coupled to research-grade CM5 chips using standard
amine coupling at a level of 9000–11,000 response units. For each
experiment, 400–600 response units of SB27 was captured on the
antibody. MHC (1–56.2 M) was injected over all flow cells at 20 l/min.
The final response was calculated by subtraction of the response to the
antibody alone from the response to the antibodyTcR complex. The
antibody surface was regenerated between each analyte injection using
ActiSep (Sterogene Bioseparations Inc.). BIAevaluation Version 3.1
(Biacore) was used for data analysis; the 1:1 Langmuir binding model
was used to calculate the kinetic constants. To allow for the capture
system, the model was modified to include an additional parameter for
the drifting base line and local fitting of the binding maxima. The
calculated Kd (Kd(calc); koff/kon) concurred with the equilibrium dissoci-
ation constant (Kd(eq)) for all reported values. This experiment was
performed twice.
To further support this result, the reverse experiment was performed,
in which HLA-B*3501LPEPLPQGQLTAY and HLA-B*3508LPEPLPQGQLTAY
were coupled to different flow cells on research-grade CM5 chips using the
MHC-specific antibody W6/32 (43), and the SB27 TcR (1–56.2 M) was
injected at 20 l/min over all flow cells. Blanks were subtracted, and data
were examined as described above.
Similar results for all experiments (n  3) were obtained. The
means  S.E. were determined.
RESULTS
Crystal Structures of HLA-B35 Complexed to Unusually
Long Viral Epitopes—To address the structural basis of bind-
ing of long epitopes to HLA-B35, we determined the crystal
structure of the immunogenic HLA-B*3508LPEPLPQGQLTAY
complex to 1.5-Å resolution (Rfac  20.3%, Rfree  22.7%) and
the non-immunogenic HLA-B*3501LPEPLPQGQLTAY complex to
1.6-Å resolution (Rfac 21.9%, Rfree 23.1%) (Table I). The two
complexes crystallize in the same space group under identical
conditions with isomorphous unit cells; and notably, the bound
epitopes do not participate in crystal contacts. Accordingly, con-
formational differences that are observed between the two crys-
tal structures can be attributed to the polymorphic amino acid
at position 156. The electron density for the bound peptides
was very clear in the HLA-B*3501LPEPLPQGQLTAY and HLA-
B*3508LPEPLPQGQLTAY structures (Fig. 1, A and B). The features
of the HLA-B*3508LPEPLPQGQLTAY complex are discussed first,
followed by the salient aspects of the other binary complex.
The LPEPLPQGQLTAY epitope is bound in the bulged
mode, with the N and C termini anchored in the A- and F-
pockets, respectively; 11 of the 12 direct hydrogen bonds be-
tween the peptide and HLA-B*3508 are located within these
pockets (Table II). The P1–C-/P–C- distance is 21.9 Å in the
HLA-B*3508LPEPLPQGQLTAY complex (Fig. 1C), which com-
pares closely with the P1–C-/P–C- distance observed in the
previously determined octameric and nonameric HLA-B*3501
complexes (44, 45). The P1-Leu binds in a standard class I
binding mode within the A-pocket, differing from that previ-
ously observed in the octameric HLA-B*3501 complex. The
TABLE I
Data collection and refinement statistics
Values in parentheses are for the highest resolution shell. r.m.s., root mean square.
HLA-B*350113-mer HLA-B*350813-mer
Data collection
Peptide LPEPLPQGQLTAY LPEPLPQGQLTAY
Temperature 100 K 100 K
Space group P212121 P212121
Cell dimensions (a, b, c) (Å) 51.25, 81.75, 110.42 50.81, 81.34, 111.00
Resolution (Å) 30 to 1.6 30 to 1.5
Total no. observations 217,659 204,388
No. unique observations 60,254 68,753
Data completeness (%) 96.7 (84) 92.1 (82.8)
No. data  2I 78.7 (39.1) 82.2 (56.6)
I/I 19.6 (2.1) 20.6 (4.3)
Rmerge (%)
a 6.5 (48.5) 6.2 (30.6)
Refinement statistics
Non-hydrogen atoms
Protein 3184 3187
Water 448 610
Resolution (Å) 1.6 1.5
Rfactor (%)
b 21.9 20.3
Rfree (%)
c 23.1 22.7
r.m.s. deviations from ideality
Bond lengths (Å) 0.007 0.004
Bond angles 1.62° 1.24°
Dihedrals 25.14° 24.64°
Impropers 0.88° 0.74°
Ramachandran plot
Most favored 90.5 92.9
And allowed region (%) 9.2 7.1
Disallowedd 0.3 0
B-factors (2)
Average main chain 18.42 13.52
Average side chain 21.16 16.22
Average water molecule 31.67 27.86
Average peptide 23.10 15.79
r.m.s. deviation bonded Bs 1.67 1.59
a Rmerge  Ihkl	 
Ihkl/Ihkl.
b Rfactor  hkl Fo 	 Fc /hklFo for all data except as indicated in Footnote c.
c 3.9 and 3.7% were used for the Rfree calculation for the HLA-B*350113-mer and HLA-B*350813-mer, respectively.
d This residue is in a region of poor electron density.
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nonstandard positioning of the P residue, initially observed in
the octameric HLA-B*3501 complex (45), is also present in the
HLA-B*3508LPEPLPQGQLTAY complex; this indicates that the
mode of binding within the P pocket is a characteristic of
HLA-B35 and is independent of peptide length. The P2-Pro
binding pocket, an anchor motif for HLA-B35, is conserved
between this structure and that described previously (45). No-
tably, there is a large network of water-mediated hydrogen
bonds between HLA-B*3508 and the LPEPLPQGQLTAY
epitope, which may partly assist in stabilizing this epitope
within the binding groove (Table II); many of these water
molecules reside in the space normally occupied by the central
region of the 8/9-mer peptides bound to HLA-B35.
The 13-mer epitope protrudes above the antigen-binding
cleft to such an extent that the extreme tip of the bulged region
of the peptide is 10 Å higher in the peptide-binding groove
in comparison with the octameric HLA-B35 complex (45)
(Fig. 1C). 34.8% of the 13-mer is solvent-exposed when bound to
HLA-B*3508, compared with only 18.6 and 25.0% for the pre-
viously described octameric and nonameric HLA-B35 com-
plexes, respectively. Despite residues P5–P9 of the epitope
making minimum direct contacts with HLA-B*3508, these res-
idues exhibit average temperature factors of only 14.5, 17.9,
31.0, 25.0, and 27.4 Å2, respectively, which compares with the
average temperature factors of 15.8 and 14.9 Å2 for the entire
13-mer epitope and the entire HLA-B*3508LPEPLPQGQLTAY
complex, respectively. The presence of three proline residues
(P2-Pro, P4-Pro, and P6-Pro) within the N-terminal region of
the peptide not only serves to raise the peptide out of the cleft,
but also provides rigidity to the bulged region of the epitope
(Fig. 1, A and B). In addition, the bulged epitope is stabilized by
residues P6–P9 forming a type IV -turn that enables the
P6-Pro side chain to pack against P10-Leu. Moreover, the bulged
region of the peptide is stabilized by intrapeptide water-mediated
hydrogen bonds as well as water-mediated hydrogen bonds to
HLA-B*3508. For example, a water molecule bridges the car-
bonyl groups between P6 and P8 of the peptide (Fig. 1, A and B).
Selection of T-cells Specific for the LPEPLPQGQLTAY Viral
Epitope Is Controlled by a Single Residue Polymorphism on the
2 Helix of the Class I Heavy Chain—HLA-B*3508 differs from
HLA-B*3501 by a single amino acid (Leu156 3 Arg), yet CTLs
recognizing the HLA-B*3501LPEPLPQGQLTAY complex are not
detected in the immune response to EBV in HLA-B*3501
individuals. To evaluate the structural basis of the influence of
polymorphism on the immunogenicity of the BZLF1-derived
13-mer, we compared the crystal structures of the HLA-B*3508
and HLA-B*3501 binary complexes bound to the LPEP-
LPQGQLTAY epitope (Fig. 2).
Analogous to the HLA-B*3508LPEPLPQGQLTAY complex, the
HLA-B*3501LPEPLPQGQLTAY complex exhibits ordered electron
density for the entire epitope, despite HLA-B*3501 making
fewer contacts with the base of the epitope as a direct result of
the Arg156 3 Leu polymorphism (Fig. 1B and Table II). This
observation correlates with HLA-B*3508LPEPLPQGQLTAY being
4 °C more thermostable than HLA-B*3501LPEPLPQGQLTAY
(data not shown). The conformation of the bound peptide in the
two structures is very similar (root mean square deviation of
0.24 Å over 13 C- atoms), but in relation to the antigen-binding
cleft, the tip (P7–P9) of the bulged loop in the HLA-B*3508 complex
is shifted away from the structurally conserved 1 helix by 0.6–0.9
Å (Fig. 2A). The HLA-B*3501LPEPLPQGQLTAY and HLA-
B*3508LPEPLPQGQLTAY complexes superpose well (root mean
square deviation of 0.37 Å over 180 C- atoms of the heavy chain);
the largest structural differences (0.5 Å at C-) are observed at
positions 105–109, 145–152, 155, 156, and 158 (Fig. 2A). Residues
105–109 represent a flexible loop, remote from the peptide-binding
site, the conformation of which is influenced by crystal contacts.
However, the structural differences in region 145–158 of the 2
helix are a result of the polymorphism at position 156 between
HLA-B*3501 and HLA-B*3508.
In HLA-B*3508, Arg156 forms an integral part of an unusual
charged cluster of residues, with its guanidinium group stack-
ing antiparallel to the guanidinium group of Arg97 (Fig. 2B).
This interaction is flanked by two salt bridging residues, Asp114
located within the F-pocket and the P3-Glu from the peptide.
FIG. 1. Structures of bulged epitopes complexed toMHC-I. 2Fo	
Fc electron density is shown in mesh format, with residues shown in
ball-and-stick format. The polymorphic residue is shown in purple. A
water molecule bridging the bulged loop is shown. A and B, structures of
HLA-B*3508 and HLA-B*3501, respectively, complexed to LPEP-
LPQGQLTAY. C, superposition of the bulged epitopes bound to MHC-I
compared with an 8-mer epitope. The 13-mer (this work) is shown in
yellow, and the 8-mer peptide (45) shown in green. The MTF-E epitope is
observed in two different conformations (25), shown in purple and orange.
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The extended conformation of the aliphatic moiety of Arg156 is
further stabilized by van der Waals interactions with Leu126,
Trp133, and Val152. Arg156 also participates in a number of
water-mediated interactions, which is due principally to the
water-filled cavity created by the central region of the peptide
arching upwards out of the cleft (Fig. 2B). These interactions
include a water-mediated hydrogen bond from Arg156 N- to
P3-Glu O-2 and Gln155 O-1, a water-mediated hydrogen bond
from Arg156 NH1,NH2 to Asp114 and Ser116 O-, and another
water molecule that bridges to P13-Tyr OH (Fig. 2B). In HLA-
B*3501, the positively charged Arg at position 156 is replaced
with the hydrophobic Leu residue, resulting in van der Waals
interactions now dominating this position. Leu156 forms van
der Waals contacts with Leu126, Val152, Leu160, and the ali-
phatic moiety of Asp114 (Fig. 2C). In addition, Leu156 forms
unfavorable van der Waals interactions with P3-Glu and Arg97,
the charges of which are presumably dissipated by the Asp114,
Arg97, and P3-Glu interaction network.
To accommodate this polymorphic residue at position 156,
there are a number of localized conformational changes. First,
Val152 in HLA-B*3508 moves away from the positively charged
Arg156. Second, in HLA-B*3501, Leu156 points toward the floor
of the antigen-binding cleft, whereas in HLA-B*3508, Arg156
runs parallel with the floor of the antigen-binding cleft (Fig. 2,
A–C). To avoid unfavorable interactions with the hydrophobic
Leu156, the carboxylate moiety of Asp114 rotates80° away and
forms a more favorable interaction with Arg97 (Fig. 2C). Third,
to compensate partly for the loss of the salt bridge between
P3-Glu and position 156 in HLA-B*3501, the P3-Glu forms a
water-mediated hydrogen bond with main chain of Val152 (Fig.
2C). In addition, the extensive network of water-mediated hy-
drogen bonds emanating from position 156 is lost in HLA-
B*3501. These conformational changes culminate in a 1-Å rigid
body shift within the prominent ridge (positions 145–152) of
the 2 helix, in which Val152 acts as the seed point for this rigid
body conformational change (Fig. 2A).
TcR Immunodominance in the Recognition of the Bulged
13-mer Determinant—Most pMHC complexes protrude mini-
mally from the plane of the antigen-binding cleft and provide a
limited number of solvent-exposed peptide side chains for TcR
interaction. In contrast, the 13-mer determinant exposes a
highly bulged region that poses a structural challenge for con-
ventional T-cell recognition. Therefore, we examined the rep-
ertoire of T-cell clonotypes in the HLA-B*3508-restricted, 13-
mer-specific CTL population. To determine the TcR usage, a
panel of V-specific monoclonal antibodies was screened
against HLA-B*3508LPEPLPQGQLTAY tetramer-expressing
CD8 cells (Fig. 3). In all three donors tested, the T-cell re-
sponse to the highly immunogenic HLA-B*3508LPEPLPQGQLTAY
complex (0.41–2% CD8 cells) was markedly restricted in V
usage. The response in donor J. W. was dominated by
TRBV20-1 and TRBV27, whereas donors C. A. and S. B. had in
common a large expansion of TRBV5-6. TcR sequence analysis
of HLA-B*3508LPEPLPQGQLTAY-specific T-cell clones confirmed
TABLE II
HLA-B*3508 contacts with the LPEPLPQGQLTAY epitope
Peptide residue MHC Type of bond 08/01differences
Leu1 O Tyr159 OH H-bond
Leu1 N Tyr171 OH, Tyr7 OH H-bond
Leu1 Arg62, Asn63, Trp167 VDWa
Pro2 Tyr7, Asn63, Ile66, Tyr99, Tyr159 VDW
Glu3 N Tyr99 OH H-bond
Glu3 N Tyr9 OH Water-mediated
Glu3 O Tyr9 OH, Asn70 N-2 Water-mediated
Glu3 O-1 Arg97 NH1,NH2 Salt bridge
Glu3 O-1 Arg156 N- Salt bridge, water-mediated 08
Glu3 O-1 Asp114 O-2 Water-mediated 01
Glu3 O-2 Gln155 O-1 Water-mediated 08
Glu3 O-2 Ala152 O Water-mediated 01
Glu3 Tyr159, Ile66 VDW
Pro4 O Asn70 N-2 Water-mediated
Pro4 Ile66, Tyr159, Leu163 VDW
Leu5 N Arg62 N-, O, Gln155 O-1 Water-mediated
Leu5 Thr69 VDW
Pro6 Gln155 VDW
Gln9 O Gln155 N-2 Water-mediated
Gln9 O-1 Thr73 O-1 Water-mediated 08
Gln9 O-1 Glu76 O-1, O-2 Water-mediated 01
Leu10 O Thr73 O-1 Water-mediated
Leu10 Asn70, Thr73 VDW
Thr11 O-1 Gln155 O-1 Water-mediated
2 bridging in 01
Thr11 N Gln155 O-1 Water-mediated
Thr11 O Arg156 NH2 Water-mediated 08
Thr11 Ala150, Val152, Lys146, Trp147 VDW
Ala12 O Trp147 N-1 H-bond
Ala12 N Glu76 O-2, Lys146 N-	 Water-mediated
Ala12 Thr73, Ser77, Glu76, Lys146,
Trp147
VDW
Tyr13 N Ser77 O- H-bond
Tyr13 OH Tyr74 OH, Ser116 O- H-bond
Tyr13 OH Arg156 NH1, Asp114 O-1,
Ser116 O-
Water-mediated 08
Tyr13 O Asn80 O-1, Lys146 N-	 H-bond
Tyr13 OXT Thr143 O-1, Tyr84 OH H-bond
Tyr13 Tyr74, Ser77, Asn80, Leu81,
Ile95, Ser116, Tyr123, Thr143,
Trp147
VDW
a VDW, van der Waals.
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the TRBV5-6 usage in donor S. B. and revealed an additional
TRBV7-2 contribution in donor S. B. and TRBV6-1 contribution
in donors S. B. and C. A. (Tables III and IV). Strikingly, regardless
of the type of V expressed, most HLA-B*3508LPEPLPQGQLTAY-
specific clones shared an identical or public TRAV19/TRAJ34
chain. Strong selection for this conserved V rearrangement in the
HLA-B*3508LPEPLPQGQLTAY response was further evident when
HLA-B*3508LPEPLPQGQLTAY tetramer-expressing CD8 cells from
all three donors were screened for TRAV19 expression (Tables III
and IV). In each donor, the public TRAV19/TRAJ34 chain was
present at high frequency. Moreover, within donors S. B. and J. W.,
there existed several independently rearranged clonotypes that
varied in codon usage within complementarity-determining region
3 (CDR3), yet expressed identical or nearly identical public
TRAV19/TRAJ34 chains. Overall, TcR recognition of the substan-
tially bulged HLA-B*3508LPEPLPQGQLTAY complex appears to be
stringently controlled by a subset of CD8 T-cells that share a
public -chain.
A Critical Role for P4–P7 in the Recognition of the HLA-
B*3508LPEPLPQGQLTAY Complex by a Dominant CTL Clono-
type—The crystal structure of the HLA-B*3508LPEPLPQGQLTAY
complex reveals a number of prominent sites (P4–P9 and P11)
that could potentially interact with the dominant TcRs. To
delineate which residues of the epitope participate in TcR in-
teractions, a fine specificity analysis was carried out on a CTL
FIG. 2. A, superposition of the two antigen-binding clefts, HLA-
B*3508 (yellow) and HLA-B*3501 (blue), highlighting the shift in the 2
helix spanning residues 145–158. B and C, impact of the polymorphism
at position on the local structure of HLA-B*3508LPEPLPQGQLTAY and
HLA-B*3501LPEPLPQGQLTAY, respectively. Residues are in ball-and-
stick format. Polar interactions are depicted as dotted lines. The poly-
morphic residue is shown in green, and the peptide is shown in yellow.
FIG. 3. The repertoire of TcR chains utilized against the EBV
LPEPLPQGQLTAY epitope is restricted. PBMCs from the EBV-
seropositive HLA-B*3508 donors C. A. (a), S. B. (b), and J. W. (c) were
co-stained with the HLA-B*3508LPEPLPQGQLTAY (LPEP-B*3508) tet-
ramer and 1 of 21 TRBV-specific antibodies. Only gated percentages of
0.02% and over were considered significant, and the designation of
TRBV follows the International ImMunoGeneTics Information System
TcR nomenclature.
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clone (SB27) that expresses a dominant TcR with the public
TRAV19/TRAJ34 -chain sequence (Fig. 4). CTL reactivity was
determined by systematically substituting each residue in the
LPEPLPQGQLTAY epitope with either glycine or tyrosine and
then assaying their recognition by SB27 CTLs. The peptides
with glycine replacements were also tested for binding to HLA-
B*3508 using the T2.B*3508 cell line to assist in interpreting
the CTL recognition data (Fig. 4). Replacement of Leu5, Pro6,
and Gln7 with glycine resulted in greatly reduced CTL recog-
nition (Fig. 4), indicating that these residues are critical deter-
minants for recognition by the SB27 clonotype; this is consist-
ent with the tyrosine replacement data (see supplemental
figure), which also indicated that Pro4, Leu5, and Gln7 are
important residues for SB27 CTL binding. Thus, the fine spec-
ificity analyses revealed that the TcR of the dominant clono-
type SB27 recognizes the N-terminal slope of the bulged pep-
tide, whereas the extreme tip and C-terminal half of the bulged
peptide are not critical determinants for TcR recognition.
The Non-immunogenic HLA-B*3501LPEPLPQGQLTAY Complex
Has a Low Affinity for the Dominant SB27 TcR—Given the
differential immunogenicity of the HLA-B*3501LPEPLPQGQLTAY
and HLA-B*3508LPEPLPQGQLTAY ligands in EBV-infected indi-
viduals, we reasoned that large bulged peptides might repre-
sent energetically challenging targets recognizable by only a
limited number of TcRs, as suggested in the repertoire analysis of
HLA-B*3508 donors. Therefore we compared the affinity and
kinetic constants for the interaction of the SB27 TcR with the
HLA-B*3508LPEPLPQGQLTAY and HLA-B*3501LPEPLPQGQLTAY
complexes (Fig. 5). To achieve this, the soluble ectodomains of
the SB27 TcR were expressed and refolded into a native conforma-
tion (data not shown). Surface plasmon resonance analysis
revealed that the affinity (Kd(eq)) of the SB27 TcR/HLA-
B*3508LPEPLPQGQLTAY interaction was 9.85  0.98 M, with
Kd(calc)  13.57  0.53 M, an on-rate (kon) of 9300  1374 M
	1
s	1, and an off-rate (koff) of 0.125  0.014 s
	1. Surface plasmon
resonance analysis of the SB27 TcR/HLA-B*3501LPEPLPQGQLTAY
interaction yieldedKd(eq) 35.23 2.8M,Kd(calc) 43.0 8M,
kon  7620  1865 M
	1 s	1, and koff  0.297  0.019 s
	1. Thus,
the non-immunogenic HLA-B*3501LPEPLPQGQLTAY complex in-
teracted with the highly selected dominant TcR clonotype at a
significantly lower affinity compared with the immunogenic
HLA-B*3508LPEPLPQGQLTAY ligand. Notably, the SB27 TcR dis-
sociated more readily from the HLA-B*3501LPEPLPQGQLTAY com-
plex (t1⁄2  2.33 s) than from the HLA-B*3508
LPEPLPQGQLTAY
complex (t1⁄2  5.54 s) (Fig. 5).
DISCUSSION
We have characterized an immunodominant or so-called
“public” CTL response to a non-canonical 13-mer epitope of the
EBV BZLF1 antigen. The entire LPEPLPQGQLTAY epitope
bound to HLA-B*3501 and HLA-B*3508 is rigid. This is in
marked contrast to the flexibility observed in previously de-
termined highly bulged epitopes (25). This rigidity can be
attributed to the three proline residues within the epitope,
the constrained conformation of this epitope, and a number of
water-mediated interactions that stabilize the epitope. Our
results now establish that the mobility of unusually long and
bulged peptides bound to MHC-I is dependent on the se-
quence and hence the local structure of the bound epitope.
Although peptide determinants that are longer than the
canonical 8/9-mer have been eluted from a number of class I
molecules, the immunogenicity of such ligands in natural im-
mune responses is largely unknown. Consequently, there are
neither any data pertaining to the diversity of the T-cell rep-
ertoire nor significant insights into how a TcR can recognize
such a complex. We have demonstrated that the HLA-
B*3508LPEPLPQGQLTAY complex is highly immunogenic, with
0.4–2% of the total CD8 CTL response directed against this
bulged target (27). This high effector frequency, detectable in
all HLA-B*3508 donors, opposes previous suggestions of large
bulging targets impeding T-cell recognition (28). Strikingly, the
T-cell repertoire against this epitope is highly restricted in all
TABLE III
CDR3 of 13-mer-specific T-cell clones
The designations of TRBV, TRBJ, TRAV, and TRAJ follow the nomenclature of the International ImMunoGeneTics Information System (37).
CTL
clone
TcR chain TcR chain
Frequencya
TRBV V(D)J TRBJ CDR3length TRAV VJ TRAJ
CDR3
length
SB9 7–2 CASSIGTGGSQPQHF 1–5 10 19 CALSGFYNTDKLIF 34 9 2/10
SB32 5–6 CASSKLGTSEETQYF 2–5 10 19 CALSGFYNTDKLIF 34 9 1/10
SB27 6–1 CASPGLAGEYEQYF 2–7 9 19 CALSGFYNTDKLIF 34 9 6/10
CA5 6–1 CASPGETEAFF 1–1 6 19 CALSGFYNTDKLIF 34 9 1/1
10 CVVSCSGNTGKLIF 37 9 1/1
SB47 5–6 CASSRTGSTYEQYF 2–7 9 16 CALRDPTGANSKLTF 56 10 1/10
a Frequency of CTL clones expressing a specific TcR.
TABLE IV
CDR3 homology from 13-mer tetramer sorted T-cells
Green areas represent the TcR family germ line, and red areas represent the region germ line.
a The designations of TRAV and TRAJ follow the nomenclature of the International ImMunoGeneTics Information System (37).
b Values signify the frequency of the TcR recovered from HLA-B*3508 LPEPLPQGQLTAY tetramer sorted CD8 T-cells.
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FIG. 5. Analysis of the binding of
the SB27 TcR to the HLA-B*3508 13-
mer (A) and the HLA-B*3501 13-mer
(B) by surface plasmon resonance.
SB27 at a range of concentrations was
passed over immobilized HLA-B*3508 (A)
or HLA-B*3501 (B), and the affinity and
kinetic constants were determined. In-
sets, the equilibrium response versus con-
centration was plotted to give an equilib-
rium affinity of 9.9 M (A) and 35.2 M
(B). RU, response units.
FIG. 4. Impact of single amino acid
substitutions within the LPEP-
LPQGQLTAY peptide on HLA-B*3508
binding and CTL recognition. pMHC
binding assays were conducted on a panel
of 13-mer analog peptides into which sin-
gle amino acid substitutions (Gly) were
introduced. Each peptide was tested at a
range of concentrations for its ability to
stabilize HLA-B*3508 expression on the
surface of the antigen-processing mutant
T2 cell line. The concentration of each
peptide required for half-maximum HLA-
B*3508 stabilization was calculated and
is shown. The CTL clone SB27 was also
tested for recognition of the peptides. A
range of peptide concentrations was used
in these chromium release assays, and
the concentration required for half-maxi-
mum lysis was calculated from these
dose-response data and is shown.
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of the HLA-B*3508 donors we have examined, with the large
majority of CTLs skewed toward the use of TRBV5-6, TRBV6-1,
and TRAV19 chains. Conservation among V chain sequences
from different donors is less stringent compared with V chain
sequences, although some of the V genes display family and
sequence homology. Thus, the TRAV19 chain, present in all
donors, is identical in amino acid sequence, including those
conserved residues encoded by N-region codons. The public
TRAV19 -chain is largely germ line-encoded, with only four
nucleotides forming the N-region, which encodes a highly con-
served Gly-Phe motif, which employs two different codons for
the Gly residue. Nearly all of the CTL clones use the J
TRAJ34 sequence, with variation from the TRAV19/TRAJ34
N-region Gly-Phe -chain combination observed only at the V-J
junction in 6 of 70 sequenced clones. Accordingly, the data
imply that strong selection of particular V chain sequences is
crucial for binding to the HLA-B*3508LPEPLPQGQLTAY ligand.
Several questions arise concerning the strategy adopted by
the restricted TcRs in recognizing such a bulged peptideMHC
complex. Is the interaction predominantly peptide-driven, akin
to antibody/hapten interactions? To enable binding, does the
TcR have unique properties, such as unusual CDR loop length
that accommodates the complex? Does the TcR adopt a diago-
nal docking mode? Does the TcR effectively crumple the bulged
region upon complexation? There appears to be nothing overtly
unusual in the CDR3 sequences or loop length of these re-
stricted TcRs. None of the other sequenced clones, including
the representative SB27 TcR, possess particularly long CDR3
loops that might be anticipated to accommodate the bulged
peptide. In addition, the CDR3 loops of the SB27 TcR are not
glycine-rich, a feature that could have been predicted to be
important in allowing plasticity of recognition of such an un-
usual epitope. Nevertheless, the slow on-rate for the SB27
TcR/HLA-B*3508LPEPLPQGQLTAY interaction is consistent with
a requirement for significant conformational adjustments of
the TcR and/or the bulged region of the peptide for optimum
binding.
Given that about one-third of the epitope is solvent-exposed,
fine specificity analysis of SB27 CTL reactivity surprisingly re-
vealed that only the N-terminal slope of the bulged epitope is
critical for TcR recognition. Given the eccentric focus on the
epitope by the SB27 TcR, it is somewhat puzzling how this TcR
could engage with both the 1 and 2 helices of the HLA-B*3508
complex in a standard diagonal docking mode. Regardless, the
SB27 TcR interacts with the HLA-B*3508LPEPLPQGQLTAY com-
plex with an affinity of 9.9 M, which is well within the range
observed for TcR/MHC-I interactions (46). Moreover, the long-
lived half-life for this interaction indicates that, once the SB27
TcR is bound, a stable complex is formed.
Maintenance of MHC polymorphism reflects selection for
induction of immunity toward diverse microbial ligands (47).
Previously, it has been shown that polymorphic residues, al-
though inaccessible to the TcR, can affect patterns of alloreac-
tivity (17, 48–50) and TcR diversity (15, 16). Remarkably, the
immunogenicity of the 13-mer epitope is controlled by a single
amino acid polymorphism between HLA-B*3508 (Arg156) and
HLA-B*3501 (Leu156) that is inaccessible to the TcR. The im-
pact of this polymorphism results in a loss of interactions
between the epitope and the heavy chain, although the confor-
mation of the bound epitope per se is not significantly affected
by the polymorphism. The impact of the polymorphism on TcR
recognition appears to reside at a rigid body shift encompassing
the ridge of the 2 helix of the MHC molecule. This effect on
MHC structure, viz. a broadening of the antigen-binding cleft
in HLA-B*3508, appears to be more favorable for TcR recogni-
tion of the HLA-B*350813-mer complex (Kd  9.9 M) com-
pared with the HLA-B*350113-mer complex, which binds to
SB27 with 4-fold reduced affinity (Kd  35.2 M). The latter
falls below the range of TcRpMHC complex affinities associ-
ated with priming of T-cell responses, being more comparable
with the affinity of very weak agonists or antagonists (51). This
finding and the lower thermostability of the HLA-B*350113-
mer binary complex correlate well with the lack of immune
response to this ligand in EBV-immune HLA-B*3501 donors
(51). Furthermore, the differential CTL recognition of the 13-
mer complexed with HLA-B*3501 versus HLA-B*3508 impli-
cates positions 145–152 as a contact region that interacts with
the SB27 TcR as in a number of other TcRpMHC complexes
(22).
The binding preference of HLA-B35 allotypes for a P2-Pro is
common among members of the HLA-B7 supertype (11, 52) and
has been preserved in MHC-I molecules found in non-human
primates (53) and rodents (54, 55). TAP translocation of cyto-
solic peptides into the endoplasmic reticulum is much less
efficient when peptides contain proline residues near their N
terminus (56–58), implying that only longer peptides that con-
tain proline distal to the N terminus will be transported by
TAP. Moreover, the endoplasmic reticulum peptide-trimming
enzyme ERAAP (4, 59–61) is unable to cleave “X–Pro” bonds,
so X-Pro-Xn peptides are likely to accumulate within the endo-
plasmic reticulum as longer precursors. Proline residues confer
conformational constraints, often resulting in the introduction
of a kink in the polypeptide chain (62, 63) that is likely to favor
the looping out of relatively long peptides from the class I-bind-
ing cleft. It would therefore be advantageous if a proportion of
class I molecules that exhibit specificity for Pro at P2 could also
present peptides longer than the canonical 8/9-mer length. This
property of MHC-I may be selected in the case of HLA-B35
based upon an ability to scavenge “indigestible” proline-con-
taining peptide ligands that are sometimes longer than usual
and that are unattractive to other class I types. The binding of
longer peptides by class I allotypes such as HLA-B27 (24) and
HLA-B35 may be facilitated because they can accommodate the
looping conformation of long peptides principally ligated
through the B- and F-pockets, whereas MHC class I molecules
such as HLA-B8, HLA-B14, and H2-Kb also possess a central
anchor residue in addition to these pockets. Our findings and
those of others (26) demonstrate that HLA-B35 functions effec-
tively in binding proline-containing epitopes of canonical and
non-canonical length that induce T-cell responses. Notably,
although the resulting TcR repertoire that can recognize such
ligands appears to be constrained, there is sufficient plasticity
to mount potent CTL responses that mediate viral immunity.
The phenomenon of T-cell immunodominance and biased usage
of particular V gene segments has been observed in the CTL
response to a number of different viral infections (64), includ-
ing EBV (65–67), measles (68), influenza (69, 70), and human
immunodeficiency virus-1 (71). Our data suggest that public
TcR usage can also reflect presentation of sterically demand-
ing, bulged ligand structures and does not solely arise from the
necessity to recognize featureless pMHC-I surfaces (72–74).
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